Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's fourth-quarter earnings call. The company reported solid fourth-quarter results, ...

Considering this and Viking's clinical trial advancements, is the stock a buy right now? Image source: Getty Images. First, let's back up and take a look at the company's story over the past year.

While the optimism surrounding the drug made Viking's stock a hot buy early last year, things have drastically cooled over the past six months during which it has plummeted more than 50%.

Both Viking and Roche are attempting to horn in on this market ... The companies plan to sell it both separately and in combination with Roche's CT-388 incretin drug. Image source: Getty Images. Both ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I remain bullish on VKTX stock.

Gerard Bottino / SOPA Images / LightRocket via Getty Images Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's fourth-quarter ...

The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.